Rhode Island 2026 Regular Session

Rhode Island Senate Bill S2877

Introduced
3/4/26  
Refer
3/4/26  
Report Pass
4/14/26  
Engrossed
4/28/26  

Caption

Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2027.

Impact

The enactment of S2877 will significantly reduce out-of-pocket expenses for individuals with diabetes who rely on insulin and related medical supplies. By ensuring that these essential items are more affordable, it seeks to improve compliance with treatment regimens among patients, who might otherwise face financial barriers to obtaining necessary care. This law can also lead to improved public health outcomes through better management of diabetes across the population.

Summary

S2877 aims to amend existing laws related to health insurance coverage for diabetes treatment in Rhode Island. The bill mandates that all individual and group health insurance policies providing medical coverage must include specific treatments and supplies for diabetes, including equipment for insulin administration and glucose monitoring. Importantly, it caps the amount a covered individual must pay at no more than $25 for a supply lasting 30 days, or for equipment designed for longer use, while simultaneously eliminating any deductible requirements for these items. This provision is set to take effect on January 1, 2027.

Contention

While the bill addresses critical healthcare needs, it has generated discussions regarding the potential economic implications for health insurance providers and the state's budget. Critics may argue that capping costs and eliminating deductibles could lead to increased premiums in the long term. Additionally, there could be concern over how new insurance mandates might affect the overall market for health insurance within the state, particularly in terms of cost-sharing structures that balance risks among insured individuals.

Companion Bills

No companion bills found.

Previously Filed As

RI S0196

Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2026.

RI H5026

Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2026.

RI S0461

Caps the total amount that a covered person is required to pay for a covered prescription inhaler, prescription device, or prescription equipment to twenty-five dollars ($25.00) per thirty (30) day supply.

RI H5302

Caps the total amount that a covered person is required to pay for a covered prescription inhaler, prescription device, or prescription equipment to twenty-five dollars ($25.00) per thirty (30) day supply.

RI S0435

Exempts from the sales tax eligible school supplies, costing less than $30.00, purchased within one week prior to the commencement of the academic year.

RI H5787

Exempts from the sales tax eligible school supplies, costing less than $30.00, purchased within one week prior to the commencement of the academic year.

RI S0051

Limits copays, coinsurance or office deductibles for services of a physical therapist to the amount authorized for the services of a primary care physician or osteopath on or after January 1, 2026.

RI H5082

Limits copays, coinsurance or office deductibles for services of a physical therapist to the amount authorized for the services of a primary care physician or osteopath on or after January 1, 2026.

RI S0115

Requires health plans that provide prescription benefits to cover at least one type of glucagon auto-injector, nasal spray, or formulation that does not require reconstitution to treat hypoglycemia. No copayment or deductible would be required.

RI H5173

Requires health plans that provide prescription benefits to cover at least one type of glucagon auto-injector, nasal spray, or formulation that does not require reconstitution to treat hypoglycemia. No copayment or deductible would be required.

Similar Bills

No similar bills found.